Artificial neural networks identify the predictive values of risk factors on the conversion of amnestic mild cognitive impairment.

The search for markers that are able to predict the conversion of amnestic mild cognitive impairment (aMCI) to Alzheimer's disease (AD) is crucial for early mechanistic therapies. Using artificial neural networks (ANNs), 22 variables that are known risk factors of AD were analyzed in 80 patients with aMCI, for a period spanning at least 2 years. The cases were chosen from 195 aMCI subjects recruited by four Italian Alzheimer's disease units. The parameters of glucose metabolism disorder, female gender, and apolipoprotein E epsilon3/epsilon4 genotype were found to be the biological variables with high relevance for predicting the conversion of aMCI. The scores of attention and short term memory tests also were predictors. Surprisingly, the plasma concentration of amyloid-beta (42) had a low predictive value. The results support the utility of ANN analysis as a new tool in the interpretation of data from heterogeneous and distinct sources.

[1]  Carol Brayne,et al.  NORMAL AGEING, IMPAIRED COGNITIVE FUNCTION, AND SENILE DEMENTIA OF THE ALZHEIMER'S TYPE: A CONTINUUM? , 1988, The Lancet.

[2]  S. DeKosky,et al.  Mild cognitive impairment, amnestic type , 2004, Neurology.

[3]  A. Newman,et al.  The metabolic syndrome, inflammation, and risk of cognitive decline. , 2004, JAMA.

[4]  E. Tangalos,et al.  Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.

[5]  H. Sauer,et al.  Pentosidine and N ε-(carboxymethyl)-lysine in Alzheimer’s disease and vascular dementia , 2003, Neurobiology of Aging.

[6]  K. Yaffe.  Metabolic Syndrome and Cognitive Disorders: Is the Sum Greater Than Its Parts? , 2007, Alzheimer disease and associated disorders.

[7]  R. Maccioni,et al.  Insulin resistance and Alzheimer's disease: molecular links & clinical implications. , 2008, Current Alzheimer research.

[8]  D. Leys,et al.  Diabetes mellitus and dementia. , 2006, Diabetes & metabolism.

[9]  D A Follmann,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans , 2022 .

[10]  C. Caltagirone,et al.  Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment. , 2009, Journal of Alzheimer's disease : JAD.

[11]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[12]  George Perry,et al.  Oxidative stress in diabetes and Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.

[13]  I. Young,et al.  Measurement of Malondialdehyde in Plasma by High Performance Liquid Chromatography with Fluorimetric Detection , 1991, Annals of clinical biochemistry.

[14]  H. Sauer,et al.  Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. , 2003, Neurobiology of aging.

[15]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[16]  E. Tangalos,et al.  CME Practice parameter: , 2022 .

[17]  A Hofman,et al.  Gender differences in the incidence of AD and vascular dementia , 1999, Neurology.

[18]  R. Mayeux,et al.  Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. , 2005, Archives of neurology.

[19]  Thomas G. Dietterich.  Approximate Statistical Tests for Comparing Supervised Classification Learning Algorithms , 1998, Neural Computation.

[20]  V. Monnier,et al.  Chromatographic Quantitation of Plasma and Erythrocyte Pentosidine in Diabetic and Uremic Subjects , 1992, Diabetes.

[21]  H. Esterbauer,et al.  Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. , 1990, Methods in enzymology.

[22]  P Knoll,et al.  Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. , 2009, Current Alzheimer research.

[23]  Sotirios Giannopoulos,et al.  Metabolic Syndrome and Alzheimer's Disease: A Link to a Vascular Hypothesis? , 2008, CNS Spectrums.

[24]  M. Macavoy,et al.  Apolipoprotein E ε4 Allele Is Unrelated to Cognitive or Functional Decline in Alzheimer’s Disease: Retrospective and Prospective Analysis , 2006, Dementia and Geriatric Cognitive Disorders.

[25]  Jigneshkumar L Patel,et al.  Applications of artificial neural networks in medical science. , 2007, Current clinical pharmacology.

[26]  J. Huber.  Diabetes, cognitive function, and the blood-brain barrier. , 2008, Current pharmaceutical design.

[27]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[28]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[29]  B. Teter,et al.  Insulin-Degrading Enzyme as a Downstream Target of Insulin Receptor Signaling Cascade: Implications for Alzheimer's Disease Intervention , 2004, The Journal of Neuroscience.

[30]  E. Mufson,et al.  Shift in the ratio of three‐repeat tau and four‐repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease , 2006, Journal of neurochemistry.

[31]  Suzanne Craft,et al.  Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. , 2007, Current Alzheimer research.

[32]  M. Tabaton,et al.  The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. , 2006, Free radical biology & medicine.

[33]  James L. McClelland,et al.  An interactive activation model of context effects in letter perception: Part 2. The contextual enhancement effect and some tests and extensions of the model. , 1982, Psychological review.

[34]  Jeffrey A. James,et al.  Amyloid imaging in mild cognitive impairment subtypes , 2009, Annals of neurology.